Manufacturers report positive data for bemcentinib in hospitalised COVID-19 in phase II trial

In the BGBC020 trial, bemcentinib, a selective AXL kinase inhibitor, found improved rates of ventilator free survival vs standard of care (90% vs 72%). It was reported to be well tolerated no safety signals of concern were identified.

Source:

Biospace Inc.